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ABSTRACT
Objective: To develop and validate a prognostic risk
index of cardiovascular mortality after cardiac resynchro-
nisation therapy (CRT).
Design: Prospective cohort study.
Setting: District general hospital.
Patients: 148 patients with heart failure (mean age 66.7
(SD 10.4) years), New York Heart Association class III or
IV, LVEF ,35%) who underwent CRT.
Interventions: CRT device implantation.
Main outcome measures: Value of a composite index
in predicting cardiovascular mortality, validated internally
by bootstrapping. The predictive value of the index was
compared to factors that are known to predict mortality in
patients with heart failure.
Results: All patients underwent assessment of 16
prognostic risk factors, including cardiovascular magnetic
resonance (CMR) measures of myocardial scarring
(gadolinium-hyperenhancement) and dyssynchrony,
before implantation. Clinical events were assessed after a
median follow-up of 913 (interquartile range 967) days. At
follow-up, 37/148 (25%) of patients died from cardio-
vascular causes. In Cox proportional hazards analyses,
(DSC) Dyssynchrony, posterolateral Scar location (both
p,0.0001) and Creatinine (p=0.0046) emerged as
independent predictors of cardiovascular mortality. The
DSC index, derived from these variables combined,
emerged as a powerful predictor of cardiovascular
mortality. Compared to patients with a DSC ,3,
cardiovascular mortality in patients in the intermediate
DSC index (3–5; HR: 11.1 (95% confidence interval (CI)
3.00 to 41.1), p=0.0003) and high DSC index (>5; HR:
30.5 (95% CI 9.15 to 101.8), p,0.0001) were higher.
Bootstrap validation confirmed excellent calibration and
internal validity of the prediction model.
Conclusion: The DSC index, derived from a standard
CMR scan and plasma creatinine before implantation, is a
powerful predictor of cardiovascular mortality after CRT.
The benefits of cardiac resynchronisation therapy
(CRT) are well established. The Cardiac
Resynchronisation in Heart Failure (CARE-HF)
study showed that, compared to optimum medical
therapy, CRT-pacing (CRT-P) led to a 36% relative
reduction in total mortality.
1 The Comparison of
Medical Therapy, Pacing and Defibrillation in
Heart Failure (COMPANION) study showed that
addition of a cardioverter defibrillator (CRT-D) led
to higher survival benefits than CRT-P.
2 Predicting
which patients derive a survival benefit from CRT,
however, remains a challenge. Numerous echocar-
diographic studies have focused on measures of
cardiac dyssynchrony as predictors of outcome,
3
but no consensus has been reached as to their
clinical applicability. In the recent Predictors of
Response to CRT (PROSPECT) study, which
adopted left ventricular (LV) reverse remodelling
as a surrogate of survival, tissue Doppler imaging-
based measures of dyssynchrony were proved to
add little value to QRS duration in predicting the
outcome of CRT.
4 No echocardiographic measure
has been validated against mortality after CRT.
Cardiovascular magnetic resonance (CMR) is the
gold standard for the in vivo assessment of
myocardial structure, function and dyssynchrony.
5
A recent pilot study has shown that a dyssyn-
chrony measure derived from a standard CMR
scan, the CMR tissue synchronisation index
(CMR-TSI), is a powerful predictor of mortality
and morbidity after CRT.
6 As well as providing
measures of dyssynchrony, CMR also allows
visualisation and quantification of myocardial
scarring with late gadolinium enhacement (CMR-
LGE).
78Importantly, the size (burden), transmur-
ality and location of a myocardial scar in the LV
free wall, the target location for LV leads, have
been linked to a poor outcome after CRT.
7–9
We have explored the value of pre-implant CMR
measures of dyssynchrony and myocardial scar-
ring, as well as more conventional heart failure risk
factors,
10 in predicting cardiovascular mortality
after CRT. This study focuses on the derivation
and validation of a clinical risk index based on a
combination of such non-invasive measures.
METHODS
Patients
A total of 148 consecutive heart failure patients
were prospectively enrolled from January 2001 to
April 2008 at a single centre (Good Hope Hospital).
Patients were selected if they were due to undergo
CRT for standard indications (ischaemic or non-
ischaemic cardiomyopathy, New York Heart
Association (NYHA) class III or IV, LV ejection
fraction (LVEF) ,35%, QRS duration >120 ms).
Until publication of the UK National Institute for
Health and Clinical Excellence (NICE) Health
Technology Appraisal in CRT in 2007,
11 the implan-
tation rate for CRT-D in the UK was very low. All
patients included in this study underwent CRT-P.
All patients had undergone coronary angiogra-
phy. The clinical diagnosis of systolic heart failure
was based on clinical criteria and evidence of
systolic dysfunction on echocardiography. The
diagnosis of ischaemic cardiomyopathy was made
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myocardial infarction,
12 the findings of coronary angiography,
or if the pattern of LGE was characteristic of a myocardial
infarction.
13 All patients gave written informed consent and the
study was approved by the North Birmingham ethics commit-
tee.
Study design
A CMR study was performed at baseline. The predictive risk
index was validated against cardiovascular death. For qualitative
comparisons with the CARE-HF study, we also considered the
composite endpoint of death from any cause or hospitalisations
for major cardiovascular events, as defined in the CARE-HF
study protocol.
1 Mortality data were collected through medical
records and, where appropriate, from interviews with patients’
caregivers. Clinical outcome data were collected on a two-
monthly basis by an investigator who was blinded to other
clinical and imaging data. Sudden cardiac death was defined as
‘‘a natural, unexpected death due to cardiac causes, heralded by
an abrupt loss of consciousness within one hour of the onset of
acute symptoms or occurring during the sleep without
worsening of heart failure in the preceding hours.’’
14
Device therapy
Implantation of CRT-P devices was undertaken using standard
techniques under local anaesthesia. The LV lead position was
chosen by the implanter, who was blinded to the CMR study.
Patients who underwent successful implantation were followed
up in a dedicated device therapy clinic. Patients in sinus rhythm
underwent trans-mitral Doppler-directed optimisation of atrio-
ventricular delay
15 before discharge and at every scheduled visit
thereafter. For patients in atrial fibrillation, right ventricular and
LV leads were implanted and a biventricular generator was used,
plugging the atrial port and programming the generator to a
ventricular-triggered mode. All patients were proved to have
functional leads and generators throughout the study period.
Cardiovascular magnetic resonance
Imaging was performed using a 1.5 Tesla scanner (Signa, GE
Healthcare, Slough, UK) and a phased array cardiac coil. A short
axis LV stack was acquired using a steady state in free
precession sequence (SSFP, repetition time 3.0–3.8 ms; excita-
tion time 1.0 ms; image matrix 2246224; field of view 36–
42 cm; flip angle 45u) in sequential 8-mm slices (2-mm interslice
gap) from the atrio-ventricular ring to apex. Acquisition was
performed during gated 8-second breath-holds. Left ventricular
end diastolic volume (LVEDV) and end-systolic (LVESV)
volume, and LVEF were quantified using manual planimetry
of all short-axis SSFP cine images with MASS analysis software
(Medis, Leiden, The Netherlands). The observer was blinded to
echocardiographic and clinical data.
The CMR-TSI was measured as previously described.
6 Briefly,
the maximum radial wall motion value of a radial wall motion
time series was chosen as the peak radial wall motion for each
LV segment. The time-dependent segmental radial wall motion
data (y) were fitted to an empirical sine wave function y = a +
b 6sin (t/RR + c). The mean segmental radial wall motion (a),
the segmental radial wall motion amplitude (b) and the
segmental phase shift of the maximum radial wall motion (c)
were extracted from the fit. The non-linear least squares fit
function implemented by Bates and DebRoy into the ‘‘nls’’
packet of R was used for the sine fit.
16 The CMR-TSI was
expressed as the SD of all segmental phase shifts of the radial
wall motion extracted from the fit. Therefore, the CMR-TSI is a
measure of the temporal dispersion of peak inward myocardial
motion throughout the cardiac cycle. A high CMR-TSI, there-
fore, denotes high temporal dispersion of inward wall motion.
For scar imaging using CMR-LGE, short-axis slices identical to
the LV stack were acquired using a segmented inversion-
recovery technique 10 minutes after the intravenous adminis-
tration of gadolinium-diethylenetriamine pentaacetic acid
(0.1 mmol/kg). Inversion times were adjusted to null normal
myocardium (260–400 ms). Scar volume was calculated by
multiplying the planimetered area of LGE in each slice by the
slice thickness. Scar volume was expressed as a percentage of LV
myocardial volume in the diastolic phase. Areas of scar were
then segmented using a 17-segment model.
17 A posterolateral
scar was defined as a scar which, in this model, was located in
segments 6, 12, 16, 5 or 11, or in the lateral half of segments 1, 7,
13, 17, 15, 10 and 4. Transmurality was also assessed using a 17-
segment model.
17 A transmural posterolateral scar was defined
as a scar with 51–100% of the LV wall, measured radially.
Statistical analysis
Continuous variables are expressed as mean (SD). Normality
was tested using the Shapiro-Wilk test. Variables which were
not normally distributed were log-transformed before statistical
analyses. Comparisons between normally distributed contin-
uous variables were made using ANOVA with Scheffe’s F
procedure for multiple comparisons. Categorical variables were
analysed using x
2 tests and Scheffe’s post-hoc test. Differences
in Kaplan-Meier survival curves between the risk groups were
assessed using the log-rank (Mantel-Cox) test. Areas under the
receiver-operating characteristic (ROC) curves (AUC) were used
to derive optimal cut-off points for the DSC index. Statistical
analyses were performed using Statview and SPSS 13.0. Harrel’s
‘‘Design’’ package version 2.1-1in R was used for predictive
modelling.
18 A two-tailed p value of ,0.05 was considered
statistically significant. In a previous study,
6 intra-observer and
inter-observer variabilities for CMR-TSI were 3.0% and 8.8%,
respectively.
Development of the risk index
In line with Harrell’s recommendations on multivariate prog-
nostic modelling,
19 20 no more than m/10 parameters were
considered, where m is the number of uncensored events, in this
case cardiovascular deaths (n=37). Candidate variables were
selected on the basis of their proved clinical, pathophysiological
and epidemiological relevance to the endpoint in question. A
measure of cardiac dyssynchrony—namely, CMT-TSI, was
included in view of previous demonstration from echocardio-
graphic
21 and radionuclide
22 studies that extremes of dyssyn-
chrony relate to a poor outcome in patients with heart failure.
Similarly, a posterolateral location of myocardial scar was
chosen in view of its negative influence on outcome after
CRT.
89Plasma creatinine was also selected given its emergence
as a predictor of mortality in patients in heart failure in
numerous studies.
10 23–27 These three variables were included in
the multiple regression model. Continuous rather than dichot-
omous variables were used wherever possible.
20 Interactions
between variables were extensively explored using interaction
terms in Cox proportional hazards models. Linearity assump-
tions were checked using Martingale residuals. Cross-product
terms were added to check for additivity assumptions. The
proportional hazards assumption was checked using Schoenfeld
residuals.
28
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Validation was implemented using bootstrapping.
19 20 29 This
non-parametric method, which estimates sampling distribu-
tions of a predictor variable by resampling with replacement
from the original sample, is, in effect, an impression of the
validity of predictions in new but similar patients. For each
group of 200 bootstrap samples, the model was refitted and
tested against the observed sample in order to derive an estimate
of the predictive accuracy and bias. This was used to select 148
‘‘new’’ patients from the original cohort, one at a time with
replacement, 200 times over. For each of these 200 samples, the
following parameters were derived: (1) the b coefficients from
Cox proportional hazards models; (2) Somer’s D rank correla-
tion index and (3) an estimate of the slope shrinkage.
19 The
apparent Somer’s D (Dapp) was derived using stepwise Cox
proportional analyses. The bootstrap-corrected performance of
the predictor equation, or ‘‘optimism’’,
20 was quantified by
assessing the difference between Somer’s D in the original
sample (Dorig) and D in the bootstrap sample (Dboot). The
average optimism, termed O, was derived by repeating the
above steps 200 times over. The bootstrap-corrected perfor-
mance of the original stepwise model, Dapp – O, is, effectively,
an honest estimate of internal validity.
20 Actual survival was
plotted against apparent estimated survival and bootstrap-
corrected estimated survival.
Calculation of the risk index
The risk prediction index was expressed as the absolute value of
the sum of the products of these variables and their b
coefficients (that is, weights) from the final stepwise multi-
variate Cox proportional hazards model, identified by Harrels’s
routine
19 20: Sb ixi =| b1x1+b2x2+…+bnxn|, where x1, x2,…xn are
the values for the variables and b1, b2,… bn are the coefficients
for each variable. For categorical variables, presence was
computed as the b coefficient and absence as zero.
Univariate analyses
Univariate Cox proportional hazards analyses were performed
after development and validation of the DSC index. These were
undertaken in order to assess the relative strength of other
variables in relation to cardiovascular mortality.
RESULTS
The characteristics of the study group are shown in table 1.
There were 20 cardiovascular deaths by one year and 28 by two
years. After a follow-up of 913 (967) days (median (interquartile
range) for events, there were 37 cardiovascular deaths. Of these,
28 were due to pump failure, eight were sudden and one patient
underwent cardiac transplantation. Of the 48 patients with a
posterolateral scar, 35 had a transmural scar and 12 had a non-
transmural scar. Scar volume in these 48 patients was 33.2%
(18.5).
Derivation and validation
Table 2 shows model outputs for the variables included in the
prediction model (DSC): Dyssynchrony, Scar location (postero-
lateral) and Creatinine. The DSC index was calculated as
follows: (2.5039 if posterolateral scar present; 0 if absent) +
0.0107. CMR-TSI (ms)) + (0.0132. plasma creatinine (mmol/l)).
Strata of the DSC index were designated as low, intermediate
or high risk, with cut-offs of ,3, between 3 and 5 and >5. These
were chosen arbitrarily for ease of use in clinical practice.
Kaplan-Meier analyses were used to assess survival according
strata of the DSC index (fig 1). Among the statistics derived
from Harrell’s routine
18 20 was a bias-corrected slope of the
Table 1 Clinical characteristics of the study group
Characteristics n=148
Age (years) 66.7 (10.4)
Men (% of patients) 114 (77)
Ischaemic aetiology (% of patients) 92 (62)
NYHA class 3.2 (0.43)
Creatinine (mmol/l) 119.8 (38.3)
Sodium (mmol/l) 139.0 (5.8)
Haemoglobin (g/dl) 14.1 (7.9)
Co-morbidity, No (% of patients)
Diabetes mellitus 24 (16)
Hypertension 40 (27)
CABG 31 (21)
Medication, No (% of patients)
Loop diuretics 129 (87)
ACE-I or ARB 136 (92)
b-blockers 81 (55)
Spironolactone 66 (45)
ECG variables
Atrial fibrillation, No (% of patients) 23 (16)
QRS duration (ms) 145.9 (26.5)
CMR variables
LVEDV (ml) 247.8 (99.5)
LVESV (ml) 200.2 (96.6)
LVEF (%) 22.5 (10.6)
CMR-TSI (ms) 100.7 (47.8)
Scar*
Volume (% of LV myocardial volume) 19.5 (20.1)
Transmural, No (% of patients) 62 (42)
Posterolateral, No (% of patients) 48 (32)
Continuous variables are expressed as mean (SD).
*Transmural scars were those with >51% transmurality.
ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin-
receptor blockers; CABG, coronary artery bypass graft; CMR-TSI,
cardiovascular magnetic resonance tissue synchronisation index;
LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular
ejection fraction; LVESV, left ventricular end-systolic volume; NYHA,
New York Heart Association.
Table 2 Final model from bootstrapped multivariable Cox proportional hazard analyses of predictors of
mortality
b coefficient (95% CI) HR (95% CI) Z-score p Value
Posterolateral scar
location
2.50 (1.60 to 3.40) 12.2 (4.97 to 30.1) 5.46 ,0.0001
CMR-TSI (ms)* 0.01 (0.00 to 0.02) 1.01 (1.00 to 1.02) 3.26 0.0011
Creatinine (mmol/l) 0.01 (0.00 to 0.02) 1.01 (1.00 to 1.02) 2.83 0.0046
Model LR x
2: 73.4,
p,0.0001
*Consequently a CMR-TSI of 100 ms is associated with a hazard ratio of 2.
CI, confidence interval; CMR-TSI, cardiovascular magnetic resonance tissue synchronisation index; HR, hazard ratio.
Heart failure and cardiomyopathy
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into account overfitting (fig 2). Somer’s Dappwas 20.70 and the
optimism (O) was 20.01. The bias-corrected performance of the
stepwise model (Dapp – O) was acceptable, at 20.69, indicating
excellent internal validity. The optimism-corrected discrimina-
tion index was 0.91; the optimism-corrected unreliability index
U was 0.01 and the overall quality index was 0.85. The ROC for
the DSC index in relation to cardiovascular mortality at various
time points is shown in figure 3.
Univariate analyses
Table 3 shows univariate model outputs for other candidate
predictors, ranked according to the likelihood ratio (LR) x
2.
Among the imaging variables, posterolateral scar location (LR
x
2: 58.6) and CMR-TSI (LR x
2: 25.5) emerged as the most
significant predictors (all p,0.0001). Scar burden (LR x
2: 13.3)
and CMR-LVEF (LRx
2: 11.1) were also strong predictors (both
p,0.001). Among circulating markers, sodium and creatinine
were significant predictors (both p,0.01), uric acid only reached
borderline significance (p=0.0808) and haemoglobin failed to
reach significance. Male gender was also a modest predictor
(p=0.0417). Age, NYHA class, QRS duration, atrial fibrillation,
diabetes or CABG failed to reach statistical significance. Similarly,
use of loop diuretics, angiotensin-converting enzyme inhibitors
(ACE)/angiotensin-receptor blockers, b-blockers or spirinolactone
failedtoemergeaspredictorsofcardiovascularmortality(datanot
shown). Although ischaemic aetiology did emerge as a significant
predictor of cardiovascular mortality in univariate analysis,
addition of scar burden to this model rendered aetiology non-
significant (data not shown). The decision not to include
ischaemic aetiology in the multiple regression model was taken
in view of its expected interaction with scar burden and scar
location (non-ischaemic cardiomyopathy is associated with little
or no scar). In addition, the diagnoses of ischaemic and non-
ischaemic cardiomyopathy were made on the basis of size,
transmurality and location of scar in the CMR scan.
DISCUSSION
Our findings have emerged in the context that there are,
hitherto, no means of predicting mortality in patients under-
going CRT. Our aim was to identify an index that could predict
cardiovascular mortality after CRT on the basis of pre-implant
variables. The DSC index, which combines pre-implant
measures of dyssynchrony and location of myocardial scar as
well as creatinine, is a novel, powerful predictor of cardiovas-
cular mortality in patients treated with CRT. Compared to
patients in the lowest risk stratum, cardiovascular mortality
values in the intermediate and high-risk strata of the DSC index
were 11.1 and 30.5 times higher by the end of the follow-up
period, respectively.
The variables from which the DSC is derived have previously
been linked to a poor outcome after CRT. Of particular
mechanistic relevance to CRT is scar burden and scar location.
This study confirms the findings of previous studies showing
that the presence of myocardial scar over the posterolateral LV
wall is a powerful predictor of cardiovascular mortality.
8 The
precise pathophysiological mechanism is still unclear, but
several factors may contribute to this observation. First,
myocardial scars are not readily excitable.
30 A posterolateral
scar reduces the volume of excitable myocardium in the vicinity
of the LV pacing stimulus and delays activation of potentially
recruitable myocardium, which is crucial for CRT.
31 Second, a
posterolateral scar also reduces the amount of myocardium
available for contraction in CRT, thereby leading to suboptimal
Figure 1 Kaplan-Meier estimates of the
time to cardiovascular death. Patients
were stratified according to pre-implant
DSC index. The event rate, number of
patients in the DSC risk stratum and the
percentage event rate are shown in
brackets. The hazard ratio (HR) and 95%
confidence intervals are also shown.
Figure 2 Calibration of predictions of mortality after cardiac
resynchronisation therapy. Graph shows actual versus bootstrap-
corrected predicted survival.
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32 Third, posterolateral
scarring may also preclude proper papillary muscle function,
which is essential for competence of the mitral valve.
As in a previous study,
6 we have shown that dyssynchrony,
assessed using CMR-TSI, predicts mortality after CRT.
6 These
findings are in contrast to numerous echocardiographic studies
showing that increasing dyssynchrony relates to increasing
benefit. In other words, our findings point towards a ‘‘too much
dyssnchrony is bad’’ paradigm, whereas echocardiographic
studies support an ‘‘any degree of dyssynchrony is good’’
paradigm of CRT. Our finding that ‘‘too much dyssynchrony is
bad’’ is, however, consistent with the finding that in non-paced
patients with heart failure, dyssynchrony, assessed by tissue
Doppler imaging, is a predictor of cardiac decompensation.
21 A
radionuclide radioscintigraphy study of patients with dilated
cardiomyopathy has also shown that a dyssynchrony index was
an independent predictor of major cardiac events, including
cardiovascular death.
22 Moreover, Bax et al
33 recently found that
beyonda limitof dyssynchrony (aseptal-to-posterior wallmotion
delay of 100 ms), CRT does not result in reverse LV remodelling.
The‘‘toomuchdyssynchronyisbad’’paradigmmightbeexpected
in view that dyssynchrony is inversely related to LVEF,
6 and
positively related to LV volumes
6 and QRS duration.
63 43 5
Together, these data suggest that the most damaged and worst
functioning left ventricles gain the least benefit from CRT. In
other words, that there is a maximum of treatable dysynchrony.
Our findings are in contrast to those of the PROSPECT study,
in which echocardiographic measures of dyssynchrony were
shown to be of little additive value to QRS duration in
predicting functional and LV volumetric changes after CRT.
4
Prominent among the findings of this study were the very high
coefficients of variation for echocardiographic dyssynchrony
measures, which were as high as 72%.
4 Current technology,
degree of training standards and analytical methods do not
allow incorporation of echocardiographic measures of dyssyn-
chrony in a generalised setting, representing a significant
limitation for their widespread use.
36 In contrast, the intra-
observer and inter-observer variabilities for CMR-TSI are as low
as 3.01% and 8.84%, respectively,
6 thereby providing the highest
accuracy and lowest intra-observer and inter-observer variabil-
ities for a dyssynchrony measure.
We have also considered other non-invasive variables which
have previously been shown to be of prognostic value in patients
with heart failure treated
78and not treated
10 26 27 with CRT. The
emergence of plasma creatinine in the predictive model is not
surprising because renal impairment is a predictor of poor
outcome in non-paced patients with heart failure.
23–26 37 We have
shown that the inverse relation between plasma creatinine and
survival still holds in patients with heart failure undergoing CRT.
Clinical application
Cardiovascular magnetic resonance imaging is becoming a key
investigation in patients with cardiomyopathy, as it provides
information on aetiology, ventricular function and prog-
nosis.
13 38 Myocardial tagging,
39 40 strain-coding
5 and velocity-
encoding
41 techniques are all capable of providing dyssynchrony
measures. These techniques, however, are highly specialised, are
not routinely available in any centre and, more importantly,
have not been validated against mortality after CRT. In
contrast, the CMR technique that allows derivation of the
DSC index involves a routine CMR-LGE scan, which is available
in any CMR centre. With the emergence of software packages
that allow rapid assessment of myocardial scars and wall
motion, the DSC index can be easily quantified.
Figure 3 Receiver-operator characteristic curves of the DSC index
against cardiovascular mortality at 1 and 2 years, and at the end of the
follow-up period. AUC, area under the curve; sens, sensitivity, spec,
specificity. Values refer to a DSC cut-off of 4.7.
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All patients in this study underwent CRT-P. Therefore, the
DSC index may not be generalisable to a population of
patients treated with CRT-D. External validation of the DSC
index in a cohort of patients undergoing CRT-D would be
desirable. As a further limitation, the use of b-blockers and
spironolactone were relatively low. While drug therapy failed
to emerge as a predictor of cardiovascular mortality, we
cannot discount the possibility that the relation between the
DSC index and cardiovascular mortality might be influenced
by more optimised medical therapy. On the other hand, in
prospective randomised controlled trials, absence of b-blocking
agents or spironolactone was not associated with a significant
survival benefit.
1
The DSC index may be useful in predicting the outcome of
CRT, but a high DSC index should not be used to deny CRT to
patients who satisfy current guideline criteria. As our study did
not include a control group, one cannot be certain the CRT-P
led to a prognostic benefit. This, however, seems likely in view
of the similarity between the prognostic risk profile of the
present cohort and that of the CRT-P arm of the CARE-HF
study (fig 4).
CONCLUSIONS
Thisstudycomprised patients with heart failure inNYHA class III
and IV, such as those included in the CARE-HF study. We have
found that in such patients, the DSC index is a powerful risk-
stratifier for cardiovascular mortality. Patients in the highest risk
stratum were more than 30 times as likely to die from
cardiovascular causes than those in the low risk stratum. These
findings are perhaps not surprising, as extreme dyssynchrony, a
posterolaterallocationofscarandpoorrenalfunctionhaveallbeen
linkedtoapooroutcomeinpatientswithheartfailure.Thepresent
studysupportstheuseofastandardCMR-LGEinprospectiveCRT
candidates, in whom pre-implantation risk stratification may
influenceclinicalmanagement.Althoughthisstudydidnotinclude
patients undergoing CRT-D, it seems unlikely that patients in the
highest DSC risk category, most of whom die of pump failure,
wouldderiveasurvivalbenefitfromCRT-D.Onthisbasis,theDSC
index may influence resource allocation.
Table 3 Univariate Cox proportional hazard analyses of predictors of mortality
b coefficient (95% CI) HR (95% CI) LR x
2 p Value
Posterolateral scar location 2.82 (1.94 to 3.70 16.8 (6.94 to 40.5) 58.6 ,0.0001
CMR-TSI (ms) 0.015 (0.01 to 0.02) 1.01 (1.01 to 1.02) 25.5 ,0.0001
Scar burden (%) 0.03 (0.01 to 0.04) 1.03 (1.01 to 1.04) 13.3 0.0001
CMR-LVEF (%) 20.06 (20.10 to 20.02) 0.94 (0.90 to 0.98) 11.1 0.0032
Sodium (mmol/l) 20.13 (0.04 to 20.04) 0.88 (0.81 to 0.96) 8.2 0.0031
Creatinine (mmol/l) 0.01 (0.00 to 0.02) 1.01 (1.00 to 1.02) 7.92 0.0049
Transmurality (transmural) 0.92 (0.26 to 1.58) 2.51 (1.29 to 4.84) 7.64 0.0057
Male gender 0.95 (20.08 to 1.99) 2.59 (0.92 to 7.32) 4.15 0.0417
Uric acid (mmol/l) 0.00 (20.00 to 0.00) 1.00 (1.00 to 1.00) 2.33 0.1265
NYHA class 0.54 (20.17 to 1.21) 1.73 (0.84 to 3.37) 2.24 0.1343
CABG 20.28 (0.18 to 20.62) 0.75 (0.53 to 1.08) 2.42 0.1196
QRS duration (ms) 0.01 (20.00 to 0.02) 1.01 (1.00 to 1.02) 1.01 0.2202
Age (years) 0.01 (0.02 to 20.01) 1.01 (0.98 to 1.05) 0.78 0.3765
Atrial fibrillation 0.15 (20.23 to 0.49) 1.16 (0.80 to 1.63) 0.64 0.4220
Diabetes mellitus 20.17 (20.55 to 0.28) 0.84 (0.57 to 1.33) 0.61 0.4324
Haemoglobin (g/dl) 20.02 (20.19 to 0.02) 0.98 (0.83 to 1.02) 0.51 0.4763
Variables are listed in order of statistical significance and likelihood ratio x
2 (LR x
2).
CABG, coronary artery bypass graft; CI, confidence interval; CMR-TSI, cardiovascular magnetic resonance tissue synchronisation
index; CMR-LVEF, cardiovascular magnetic resonance left ventricular ejection fraction; HR, hazard ratio; NYHA, New York Heart
Association.
Figure 4 Comparison of events in the
present cohort and in the CARE-HF study.
Qualitative comparison of Kaplan-Meier
survival estimates for the combined
endpoint of death from any cause or
hospitalisations for major cardiovascular
events (MCE) for patients included in this
study as well as those in the CRT-P and
the optimum medical treatment (OPT)
arms the CARE-HF study. Follow-up time
in the present cohort has been truncated
to 1500 days. Modified with permission
from Cleland et al.
1
Heart failure and cardiomyopathy
1624 Heart 2009;95:1619–1625. doi:10.1136/hrt.2009.173880Acknowledgements: We are grateful to Professor Nick Freemantle for statistical
advice. We are also grateful to Lisa Ball, Janet Brashaw-Smith and Nick Irwin for their
input in the follow-up of patients included in this study.
Funding: The role of the industry sponsors was, exclusively, to fund research
fellowships. BS, who was employed by Medtronic Inc, at the time of writing, provided
statistical expertise and was involved in the review of the manuscript. The other
authors had full independence from the sponsors with regard to study design, data
collection, interpretation and manuscript preparation.
Competing interests: SC and PF have research fellowships sponsored by Medtronic
Inc. BS was an employee of Medtronic Inc. REAS, PJ and FL have received
sponsorship from Medtronic Inc. FL and KK have also received sponsorship from St
Jude Medical. MPF is a consultant for Medtronic Inc. AA has research fellowships
sponsored by Medtronic Inc, Boston Scientific Corp and St Jude Medical, andi s
consultant for Medtronic Inc, and Sorin. He has also received speaker fees from
Medtronic Inc, Sorin and Biotronik.
Provenance and peer review: Not commissioned; externally peer reviewed.
REFERENCES
1. Cleland JGF, Daubert J-C, Erdmann E, et al, for the Cardiac Resynchronization-Heart
Failure (CARE-HF) study investigators. The effect of cardiac resynchronization on
morbidity and mortality in heart failure. N Engl J Med 2005;352:1539–49.
2. Bristow MR, Saxon LA, Boehmer J, et al, for the Comparison of Medical Therapy,
Pacing and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac
resynchronization therapy with or without an implantable defibrillator in advanced
heart failure. N Engl J Med 2004;350:2140–50.
3. Bax JJ, Abraham T, Barold SS, et al. Cardiac resynchronization therapy: Part 1—
Issues before device implantation. J Am Coll Cardiol 2005;46:2153–67.
4. Chung E, Leon A, Tavazzi L, et al. Results of the predictors of response to CRT
(PROSPECT) Trial. Circulation 2008;117:2608–16.
5. Lardo AC, Abraham TP, Kass DA. Magnetic resonance imaging assessment of
ventricular dyssynchrony: current and emerging concepts. J Am Coll Cardiol
2005;46:2223–8.
6. Chalil S, Stegemann B, Muhyaldeen S, et al. Intraventricular dyssynchrony predicts
mortality and morbidity following cardiac resynchronization therapy: a study using
cardiovascular magnetic resonance tissue synchronization imaging. J Am Coll Cardiol
2007;50:243–52.
7. White JA, Yee R, Yuan X, et al. Delayed enhancement magnetic resonance imaging
predicts response to cardiac resynchronization therapy in patients with
intraventricular dyssynchrony. J Am Coll Cardiol 2006;48:1953–60.
8. Chalil S, Stegemann B, Muhyaldeen S, et al. Effect of posterolateral left ventricular
scar on mortality and morbidity following cardiac resynchronization therapy. Pacing
Clin Elctrophysiol 2007;10:1201–7.
9. Chalil S, Foley P, Muyhaldeen S, et al. Late gadolinium enhancement-cardiovascular
magnetic resonance as a predictor of response to cardiac resynchronization therapy
in patients with ischaemic cardiomyopathy. Europace 2007;9:1031–7.
10. Aaronson KD, Schwartz JS, Chen TM, et al. Development and prospective validation
of a clinical index to predict survival in ambulatory patients referred for cardiac
transplant evaluation. Circulation 1997;95:2660–7.
11. Barnett D, Phillips S, Longson C. Cardiac resynchronisation therapy for the treatment
of heart failure: NICE technology appraisal guidance. Heart 2007;93:1134–5.
12. Alpert JS, Thygesen K, Antman E, et al. Myocardial infarction redefined—a
consensus document of the Joint European Society of Cardiology/American College of
Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol
2000;36:959–69.
13. Assomull RG, Prasad SK, Lyne J, et al. Cardiovascular magnetic resonance, fibrosis,
and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 2006;48:1977–85.
14. Myerburg RJ, Castellanos A. Cardiac arrest and sudden cardiac death. In:
Braunwald E, ed. Heart disease: a textbook of cardiovascular medicine. New York: WB
Saunders, 1997:742–79.
15. Ritter P, Padeletti L, Gillio-Meina L, et al. Determination of the optimal
atrioventricular delay in DDD pacing: comparison between echo and peak endocardial
acceleration measurements. Europace 1999;1:126–30.
16. Bates DM, Watts DG. Nonlinear regression analysis and its applications. Chichester:
Wiley, 1988.
17. Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial
segmentation and nomenclature for tomographic imaging of the heart: a statement
for healthcare professionals from the Cardiac Imaging Committee of the Council of the
American Heart Association. Circulation 2002;105:539–42.
18. Harrell FJ. The Design Package. 2007.
19. Harrell FJ, Lee K, Califf R, et al. Regression modelling strategies for improved
prognostic prediction. Stat Med 1984;3:143–52.
20. Harrell FJ, Lee K, Mark D. Multivariate prognostic models: issues in developing
models, evaluating assumptions and adequacy, and measuring and reducing errors.
Stat Med 1996;15:361–87.
21. Bader H, Garrigue S, Lafitte S, et al. Intra-left ventricular electromechanical
asynchrony: a new predictor of severe cardiac events in heart failure patients. JA m
Coll Cardiol 2004;43:248–56.
22. Fauchier L, Marie O, Casset-Senon D, et al. Interventricular and intraventricular
dyssynchrony in idiopathic dilated cardiomyopathy. A prognostic study with Fourier
phase analysis of radionuclide angioscintigraphy. J Am Coll Cardiol 2002;40:2022–30.
23. Dries DL, Exner DV, Domanski MJ, et al. The prognostic implications of renal
insufficiency in asymptomatic and symptomatic patients with left ventricular systolic
dysfunction. J Am Coll Cardiol 2000;35:681–9.
24. Smilde TD, Hillege HL, Navis G, et al. Impaired renal function in patients with
ischemic and nonischemic chronic heart failure: association with neurohormonal
activation and survival. Am Heart J 2004;148:165–72.
25. Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation,
and survival in patients with chronic heart failure. Circulation 2000;102:203–10.
26. Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients
hospitalized for heart failure: derivation and validation of a clinical model. JAMA
2003;290:2581–7.
27. Anker S, Doehner W, Rauchhaus M, et al. Uric acid and survival in chronic heart
failure: validation and application in metabolic, functional, and hemodynamic staging.
Circulation 2003;107:1991–7.
28. Schoenfeld D. Partial residuals for the proportional hazards regression model.
Biometrika 1982;69:239–41.
29. Efron B. Bootstrap method: another look at the jacknife. Ann Stat 1979;7:1–26.
30. Tedrow U, Maisel W, Epstein L, et al. Feasibility of adjusting paced left ventricular
activation by manipulating stimulus strength. J Am Coll Cardiol 2004;44:2249–51.
31. Breithardt OA, Stellbrink C, Kramer AP, et al. Echocardiographic quantification of left
ventricular asynchrony predicts an acute hemodynamic benefit of cardiac
resynchronization therapy. J Am Coll Cardiol 2002;40:536–45.
32. Bleeker GB, Kaandorp TAM, Lamb HJ, et al. Effect of posterolateral scar tissue on
clinical and echocardiographic improvement after cardiac resynchronization therapy.
Circulation 2006;113:969–76.
33. Bax JJ, Bleeker GB, Marwick TH, et al. Left ventricular dyssynchrony predicts
response and prognosis after cardiac resynchronization therapy. J Am Col Cardiol
2004;44:1834–40.
34. Donal E, Tournoux F, Leclercq C, et al. Assessment of longitudinal and radial
ventricular dyssynchrony in ischemic and nonischemic chronic systolic heart failure: a
two-dimensional echocardiographic speckle-tracking strain study. J Am Soc
Echocardiogr 2008;21:58–65.
35. Marcassa C, Campini R, Verna E, et al. Assessment of cardiac asynchrony by
radionuclide phase analysis: correlation with ventricular function in patients with
narrow or prolonged QRS interval. Eur J Heart Fail 2007;9:484–90.
36. Conca C, Faletra FF, Miyazaki C, et al. Echocardiographic parameters of mechanical
synchrony in healthy individuals. Am J Cardiol 2009;103:136–42.
37. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction
of survival in heart failure. Circulation 2006;113:1424–33.
38. McCrohon JA, Moon JJC, Prasad SK, et al. Differentiation of heart failure related to
dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced
cardiovascular magnetic resonance. Circulation 2003;108:54–9.
39. Wyman BT, Hunter WC, Prinzen FW, et al. Mapping propagation of mechanical
activation in the paced heart with MRI tagging. Am J Physiol 1999;276:H881–91.
40. Helm RH, Lecquercq C, Faris Q, et al. Cardiac dyssynchrony analysis using
circumferential versus longitudinal strain: Implications for assessing cardiac
resynchronization. Circulation 2005;111:2760–7.
41. Westenberg JJM, Lamb H, van der Geest RJ, et al. Assessment of left ventricular
dyssynchrony in patients with conduction delay and idiopathic dilated
cardiomyopathy. J Am Coll Cardiol 2006;47:2042–8.
Heart failure and cardiomyopathy
Heart 2009;95:1619–1625. doi:10.1136/hrt.2009.173880 1625